跳至主要内容
临床试验/NCT00978549
NCT00978549已完成3 期

Randomised Phase III Study of Docetaxel vs Active Symptom Control in Patients With Relapsed Oesophago-gastric Adenocarcinoma

Cambridge University Hospitals NHS Foundation Trust16 个研究点 分布在 1 个国家目标入组 320 人开始时间: 2008年4月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
320
试验地点
16
主要终点
Overall survival

研究概览

简要总结

RATIONALE: Analgesics, antiemetics, steroids, and radiation therapy are effective in helping to control symptoms caused by cancer. It is not yet known whether these treatments are more effective when given with or without docetaxel in treating patients with relapsed esophageal cancer or stomach cancer.

PURPOSE: This randomized phase II trial is studying symptom control given together with docetaxel to see how well it works compared with symptom control given without docetaxel in treating patients with relapsed esophageal cancer or stomach cancer.

详细描述

OBJECTIVES:

Primary

  • To compare overall survival of patients with relapsed adenocarcinoma of the esophagus or stomach after treatment with docetaxel and active symptom control vs active symptom control alone.

Secondary

  • To determine the time to documented progression in patients treated with docetaxel.
  • To assess response rates to docetaxel in patients treated with docetaxel.
  • To determine toxicity of docetaxel in patients treated with docetaxel.
  • To assess the quality of life of these patients.
  • To evaluate the health economic impact.

研究设计

研究类型
Interventional
分配方式
Randomized
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Overall survival

次要结局

  • Time to documented progression (arm I)
  • Response rate (arm I)
  • Toxicity (arm I)
  • Quality of life as assessed by EORTC QLQ-C30 and -STO22
  • Health economic evaluation as assessed by EQ-5D

研究者

研究点 (16)

Loading locations...

相似试验